1. A 79-year-old man with a hip fracture sustained after a mechanical fall is brought to the operating room for hemiarthroplasty. He has been nil by mouth for 14 hours and his most recent blood pressure is 102/64 mmHg. The anesthesiologist administers propofol 1.8 mg/kg IV over 30 seconds for induction. Blood pressure immediately falls to 58/32 mmHg, requiring bolus phenylephrine and a 500 mL crystalloid bolus to restore perfusion pressure. Which explanation best accounts for the severity of this hypotensive response and what modification would have been most appropriate?

• A) The hypotension resulted from propofol-induced release of histamine from mast cells, producing systemic vasodilation — the appropriate modification would have been prophylactic diphenhydramine 50 mg IV before induction to block H1 receptors and prevent the histaminergic component of propofol-induced vasodilation.
• B) The hypotension reflects propofol's selective inhibition of vasopressin release from the posterior pituitary — the appropriate modification would have been prophylactic vasopressin 0.03 units/min IV infusion initiated before induction to maintain systemic vascular resistance independently of baroreceptor-mediated compensation.
• C) The hypotension resulted from propofol activating GABA-A receptors in the adrenal medulla, suppressing catecholamine release and producing a state of functional adrenal insufficiency during induction — the modification should have been hydrocortisone 100 mg IV before induction and a slower propofol administration rate.
• D) Multiple compounding factors explain the severity: this patient has age-related reduction in volume of distribution (producing higher peak propofol concentrations after a standard dose), reduced hepatic clearance (prolonging drug effect), blunted baroreceptor reflex (preventing compensatory tachycardia), and acute hypovolemia from prolonged fasting and hemorrhage around the fracture site (reducing preload and the cardiovascular reserve available to buffer vasodilation) — the appropriate modifications were dose reduction to approximately 1.0 mg/kg or less, slow administration over 60 to 90 seconds or by titrated increments, and volume resuscitation or vasopressor pre-treatment before induction.
• E) The hypotension was caused by propofol's direct negative chronotropic effect on the sinoatrial node — the appropriate modification was atropine 0.6 mg IV before induction to prevent the bradycardia that is the primary driver of propofol-induced hypotension in elderly patients.

2. A 58-year-old man with severe aortic stenosis receives etomidate 0.3 mg/kg IV for induction of general anesthesia. No premedication was given. Immediately after loss of consciousness, he develops brief, rhythmic jerking movements of his arms and trunk lasting approximately 20 seconds. A medical student on the team calls out "seizure!" and a resident prepares to administer lorazepam 2 mg IV. The attending anesthesiologist stops the resident. Which of the following best explains why the attending's intervention was correct?

• A) The attending stopped the resident because lorazepam at 2 mg IV would reverse etomidate's GABA-A-mediated anesthesia — since lorazepam and etomidate compete for the same beta subunit binding site, administering lorazepam would displace etomidate from its receptor and cause the patient to emerge from anesthesia at a critical induction moment.
• B) The movements represent etomidate-induced myoclonus — a cortical disinhibition phenomenon that is not seizure activity and is not associated with epileptiform EEG discharges; administering lorazepam is unnecessary, exposes the patient to additional respiratory depression, and risks delaying the surgical procedure, when the correct response is to recognize the benign nature of the phenomenon and allow it to resolve, or to prevent it in future cases with opioid or benzodiazepine premedication before etomidate.
• C) The attending stopped the resident because the correct treatment for etomidate-induced seizures is not lorazepam but rather propofol 0.5 mg/kg IV, which terminates etomidate-induced ictal activity more reliably than benzodiazepines by providing broader-spectrum GABA-A receptor engagement at both alpha and beta subunit sites simultaneously.
• D) The movements represent succinylcholine fasciculations being misidentified as myoclonus — they occur because etomidate is frequently co-administered with succinylcholine, and the fasciculations from succinylcholine-mediated depolarizing neuromuscular blockade are commonly mistaken for etomidate myoclonus by inexperienced observers; no treatment is needed but the distinction is pharmacologically important.
• E) The attending stopped the resident because lorazepam is absolutely contraindicated within 30 minutes of etomidate administration — the combination produces irreversible inhibition of 11-beta-hydroxylase through a synergistic interaction between etomidate's imidazole mechanism and lorazepam's benzodiazepine mechanism, causing profound adrenocortical suppression that would be fatal in a patient with severe cardiac disease.

3. A 24-year-old woman with a documented family history of malignant hyperthermia (MH) presents for elective laparoscopic appendectomy. Her preoperative MH status was noted in the chart but not communicated to the covering anesthesiologist at shift change. Anesthesia is induced with propofol and rocuronium, and maintenance is begun with sevoflurane 2% in oxygen. Fifteen minutes into the case, the patient develops masseter rigidity, rising end-tidal CO2 despite increased minute ventilation, a temperature of 39.4°C (rising 1°C every 5 minutes), and generalized muscle rigidity. Which response correctly identifies what has occurred, the responsible agent, and the immediate required intervention?

• A) The patient is experiencing propofol infusion syndrome triggered by the induction dose — the rising CO2 and temperature reflect mitochondrial uncoupling from propofol's lipid emulsion; the responsible agent is propofol; immediate management is to stop propofol, switch to volatile agent maintenance, and administer sodium bicarbonate for the metabolic acidosis.
• B) The patient is experiencing neuroleptic malignant syndrome triggered by rocuronium's dopamine receptor blocking properties in the basal ganglia — rocuronium at intubating doses can precipitate NMS in genetically susceptible patients; the responsible agent is rocuronium; immediate management is bromocriptine and dantrolene.
• C) The patient is experiencing a hypermetabolic crisis from unrecognized thyroid storm — the preoperative MH notation distracted the team from recognizing the true diagnosis; the responsible agent is surgical stress combined with undiagnosed hyperthyroidism; immediate management is esmolol, propylthiouracil, and potassium iodide.
• D) The patient is experiencing an acute anaphylactic reaction to sevoflurane's metabolic byproduct compound A (formed during low-flow anesthesia with soda lime) — compound A triggers mast cell degranulation in susceptible patients, producing histamine-mediated hyperthermia and muscle rigidity; immediate management is epinephrine 0.5 mg IM and IV antihistamines.
• E) The patient is experiencing a malignant hyperthermia crisis triggered by sevoflurane — volatile halogenated anesthetic agents are absolute MH triggers in susceptible patients, causing uncontrolled calcium release from the skeletal muscle sarcoplasmic reticulum through mutant ryanodine receptor 1 (RYR1) channels; immediate management requires calling for help, stopping sevoflurane immediately, switching to TIVA with propofol (which does not trigger MH), hyperventilating with 100% oxygen to clear CO2, and administering dantrolene (a ryanodine receptor blocker that is the specific antidote) at 2.5 mg/kg IV repeated every 5 minutes until the crisis is controlled, to a maximum of 10 mg/kg.

4. A 44-year-old woman is in the medical ICU with severe acute pancreatitis requiring mechanical ventilation. She has been receiving propofol at 5 mg/kg/hr for 58 hours for sedation. The morning laboratory results show: arterial pH 7.21, bicarbonate 14 mEq/L, anion gap 22 mEq/L (normal less than 12), creatine kinase 8,400 U/L (baseline 180 U/L), serum lactate 4.8 mmol/L. Her ECG shows new right precordial ST elevation in a Brugada-like pattern. Her urine output is adequate but her urine is dark brown. What is the most important immediate next step in management?

• A) Stop the propofol infusion immediately — the clinical constellation of new high anion gap metabolic acidosis, markedly elevated creatine kinase, Brugada-pattern ECG changes, and dark urine (myoglobinuria) in the context of high-dose prolonged propofol infusion is diagnostic of propofol infusion syndrome (PRIS); the single most important intervention is removing the causative agent; an alternative sedative (such as dexmedetomidine, midazolam, or ketamine) should be substituted, and supportive care initiated including cardiac monitoring and assessment of renal function.
• B) Administer sodium bicarbonate 150 mEq IV immediately — the metabolic acidosis is the most life-threatening abnormality and must be corrected before addressing the underlying cause; propofol can be continued at a reduced dose of 2 mg/kg/hr while the acid-base status is normalized.
• C) Order a stat echocardiogram to rule out new-onset cardiomyopathy from the underlying pancreatitis — the ECG changes and metabolic acidosis are most likely caused by pancreatitis-related myocardial inflammation and systemic inflammatory response syndrome; propofol is not the cause and should be continued for sedation while the cardiac workup is completed.
• D) Administer dantrolene 2.5 mg/kg IV — the combination of hyperthermia, rhabdomyolysis, and metabolic acidosis in a critically ill patient on a sedative infusion is consistent with malignant hyperthermia triggered by propofol; dantrolene is the specific antidote and should be given immediately while the propofol is converted to a volatile agent.
• E) Increase the propofol infusion to 6 mg/kg/hr and add a triglyceride infusion — the metabolic acidosis and elevated lactate indicate that the patient's energy substrate delivery is insufficient for her metabolic demands; increasing the caloric content of the propofol emulsion and adding supplemental triglycerides will correct the energy deficit driving the lactic acidosis and rhabdomyolysis.

5. A 32-year-old woman with a documented history of acute intermittent porphyria (AIP) — a hereditary disorder of heme biosynthesis characterized by potentially life-threatening attacks of abdominal pain, autonomic instability, and neurological dysfunction — requires emergency intubation for airway protection following a drug overdose. The covering resident selects thiopental 4 mg/kg IV for rapid sequence induction, stating "it's the fastest-onset barbiturate and she needs a secure airway now." A senior anesthesiologist immediately intervenes. Which response best explains the intervention and the correct management?

• A) The senior anesthesiologist intervened because thiopental's highly alkaline pH (approximately 10.5) creates an unacceptably high risk of laryngospasm in a patient with porphyria-related autonomic instability — the correct alternative is etomidate, which has a neutral pH and does not provoke autonomic reflexes during laryngoscopy.
• B) The senior anesthesiologist intervened because thiopental requires a minimum 10-minute infusion for safe induction in porphyria patients — rapid bolus administration in AIP triggers an acute attack through rate-dependent delta-aminolevulinic acid (ALA) synthase induction; a slow infusion over 10 minutes is safe and appropriate.
• C) The senior anesthesiologist intervened because thiopental is absolutely contraindicated in patients with acute porphyrias — barbiturates induce delta-aminolevulinic acid (ALA) synthase, the rate-limiting enzyme in heme biosynthesis, driving accumulation of toxic porphyrin precursors that can precipitate a life-threatening acute porphyric crisis including severe abdominal pain, autonomic instability, and potentially fatal respiratory paralysis; the correct agents for induction in porphyria are propofol (considered safe, does not induce ALA synthase) or ketamine (also considered safe), both of which can achieve rapid sequence induction when combined with succinylcholine or rocuronium.
• D) The senior anesthesiologist intervened because thiopental is contraindicated in drug overdose patients specifically — barbiturates potentiate CNS depression from most overdose agents through GABA-A receptor synergism, creating unpredictable depth of anesthesia; the correct alternative in overdose patients is ketamine, whose NMDA antagonism does not synergize with GABA-A-active overdose drugs.
• E) The senior anesthesiologist intervened because thiopental requires dose reduction by 80% in porphyria patients due to reduced plasma protein binding from the elevated bilirubin characteristic of porphyric liver disease — the standard 4 mg/kg dose would produce dangerous overdose; a dose of 0.8 mg/kg would be appropriate.

6. A 52-year-old man with a large anterior neck mass and limited mouth opening requires awake fiberoptic intubation (awake FOI) before induction of general anesthesia. The airway team plans topical anesthesia of the airway with nebulized lidocaine. The anesthesia resident suggests administering ketamine 1.5 mg/kg IV, reasoning that "ketamine preserves spontaneous ventilation, so it's perfect for an awake airway technique." The attending anesthesiologist disagrees with this plan. Which response best explains the attending's concern?

• A) The attending disagrees because ketamine at 1.5 mg/kg IV produces excessive bronchodilation, which — while normally beneficial — would cause turbulent airflow through the trachea that interferes with the fiberoptic bronchoscope image quality and makes anatomical landmarks difficult to identify during the intubation.
• B) The attending disagrees because ketamine's sympathomimetic cardiovascular stimulation would raise the patient's blood pressure to dangerous levels during the procedure, and topical lidocaine cannot be safely applied to a hypertensive patient because systemic absorption of nebulized lidocaine in combination with ketamine-induced hypertension risks hypertensive emergency.
• C) The attending disagrees because ketamine is absolutely contraindicated in patients with anterior neck masses — the sympathomimetic cardiovascular stimulation from ketamine increases venous engorgement of the neck mass and raises the risk of tracheal compression during induction, making it unsuitable for any patient with a neck mass regardless of airway anatomy.
• D) The attending disagrees because ketamine at 1.5 mg/kg IV produces full dissociative anesthesia — the patient will be unaware, uncooperative, and unable to follow commands, which defeats the fundamental purpose of an awake fiberoptic intubation technique (which requires a conscious, cooperative patient who can maintain their own airway and respond to instructions); additionally, ketamine increases oral and airway secretions through its sympathomimetic mechanism, worsening visualization during fiberoptic bronchoscopy; the correct agent for awake FOI sedation is dexmedetomidine, which produces arousable cooperative sedation with preserved ventilation and reduced secretions relative to ketamine.
• E) The attending disagrees because ketamine is contraindicated with topical lidocaine — the combination produces additive sodium channel blockade throughout the central nervous system, and ketamine's CNS sodium channel effects combined with systemically absorbed lidocaine from nebulization create an unacceptable risk of cardiac arrhythmia from combined sodium channel toxicity.

7. A 51-year-old man with a 12-year history of epilepsy, currently maintained on clonazepam 2 mg twice daily for seizure control, undergoes colonoscopy with midazolam 4 mg IV for procedural sedation. In the recovery area, he remains drowsy 45 minutes after the procedure. An endoscopy nurse administers flumazenil 0.2 mg IV to accelerate his discharge. Within 90 seconds, the patient has a generalized tonic-clonic seizure lasting 90 seconds. Which pharmacological analysis best explains this outcome?

• A) The seizure resulted from flumazenil's inverse agonist activity at benzodiazepine receptors — flumazenil does not simply block the receptor but actively drives it toward an excitatory conformation, directly generating epileptiform discharges regardless of the patient's underlying seizure history or degree of benzodiazepine dependence.
• B) Two pharmacological mechanisms converged to produce the seizure: the patient has physical dependence on clonazepam from 12 years of daily use, meaning his nervous system has adapted to chronic benzodiazepine receptor occupancy by upregulating excitatory pathways; flumazenil's competitive antagonism abruptly displaced clonazepam from benzodiazepine receptors, removing the inhibitory tone the nervous system had adapted to and precipitating acute withdrawal seizure; this risk was compounded by flumazenil's independent property of lowering seizure threshold in patients with epilepsy, making this patient doubly vulnerable — both dependent and epileptic.
• C) The seizure was caused by a pharmacokinetic interaction between flumazenil and clonazepam — flumazenil is a potent CYP3A4 (cytochrome P450 3A4) inhibitor that raised the plasma clonazepam concentration to supratherapeutic levels within minutes of administration, producing paradoxical clonazepam toxicity manifesting as a clonic seizure-like state rather than expected sedation.
• D) The seizure resulted from flumazenil reversing midazolam's anticonvulsant protection in an epilepsy patient — midazolam at procedural doses provides significant anticonvulsant protection equivalent to a therapeutic benzodiazepine dose; removing this protection with flumazenil exposed a baseline epileptic discharge that midazolam had been suppressing throughout the procedure; clonazepam was not involved because its chronic administration produces complete tolerance to its anticonvulsant effect.
• E) The seizure was caused by resedation from clonazepam redistributing from peripheral tissue compartments into the CNS after flumazenil's competitive blockade was overcome — the high tissue concentration of clonazepam built up over 12 years of chronic use produced a massive rebound CNS concentration when flumazenil cleared, paradoxically producing a toxic clonazepam level that manifested as seizure activity rather than sedation.

8. During a TIVA case for abdominal surgery, the anesthesiologist is using a TCI (target-controlled infusion) pump with the Schnider pharmacokinetic model targeting an effect-site propofol concentration of 3.5 mcg/mL. Thirty minutes into the maintenance phase, the processed EEG monitor shows a BIS value of 72 and the patient makes a purposeful movement in response to surgical incision. The TCI pump display confirms the target has been set at 3.5 mcg/mL for the last 20 minutes. The anesthesiologist's colleague suggests "the pump model says 3.5 mcg/mL — the patient must just be a high responder to pain, not light on anesthesia." Which response correctly identifies the error in this reasoning and the appropriate action?

• A) The colleague is correct — a BIS of 72 during surgery with purposeful movement indicates that the surgical stimulation is exceeding the analgesic capacity of the technique; the appropriate action is to increase the remifentanil infusion rate rather than the propofol target, because BIS values above 60 during movement reflect inadequate analgesia rather than inadequate hypnosis.
• B) The colleague is correct that 3.5 mcg/mL is an adequate target, but the Schnider model is unreliable in abdominal surgery because peritoneal insufflation alters the volume of distribution — the appropriate action is to switch to the Marsh model, which accounts for abdominal compartment effects, and maintain the same 3.5 mcg/mL target.
• C) The BIS of 72 indicates the patient is in the optimal depth range for regional awareness monitoring — BIS values of 65 to 80 are the recommended target during TIVA to balance awareness prevention with the risk of excessive depth; the movement is a normal reflex response to nociception that occurs even at adequate anesthetic depths and does not require any change in management.
• D) The appropriate action is to administer a propofol bolus of 2 mg/kg and then stop the TCI infusion entirely — TCI systems are not reliable during abdominal surgery and should be replaced with volatile agent maintenance whenever purposeful movement occurs, because movement under TCI indicates a fundamental failure of the pharmacokinetic model.
• E) The colleague's reasoning is incorrect — TCI model predictions can diverge from true plasma and effect-site concentrations by 20 to 30% or more due to pharmacokinetic variability between individuals; a BIS of 72 with purposeful movement during surgery strongly indicates that the true propofol effect-site concentration is below the model-predicted 3.5 mcg/mL (the target range for surgical anesthesia is BIS 40 to 60); the appropriate action is to increase the propofol TCI target (to 4.0 to 4.5 mcg/mL or higher as needed) and consider a supplemental bolus, using the BIS value and clinical response as the true guide to anesthetic depth rather than trusting the model prediction.

9. A 67-year-old man with severe COPD (chronic obstructive pulmonary disease) and a FEV1 (forced expiratory volume in 1 second) of 28% predicted presents to the emergency department in acute hypercapnic respiratory failure with a pH of 7.22 and PaCO2 of 88 mmHg. He is in moderate respiratory distress with audible wheeze and accessory muscle use. Non-invasive ventilation has failed and the decision is made to intubate. His blood pressure is 94/58 mmHg. Which induction agent is best suited for this patient and what properties make it the most appropriate choice?

• A) Ketamine — its sympathomimetic mechanism (catecholamine release and reuptake inhibition) typically supports blood pressure rather than reducing it, addressing the concurrent hemodynamic instability; its potent bronchodilatory properties (via beta-2 adrenergic activation of airway smooth muscle and possibly direct smooth muscle relaxation) are directly beneficial in a patient with severe obstructive airway disease and active bronchospasm; these two properties together make it the most pharmacologically appropriate induction agent in this specific clinical scenario.
• B) Propofol at a reduced dose of 0.5 mg/kg IV — at this low dose, propofol's cardiovascular depression is minimal and its mild bronchodilatory properties provide adequate airway smooth muscle relaxation; the key advantage is its antiemetic effect, which reduces the risk of aspiration pneumonia if the patient vomits during induction given his elevated intrathoracic pressures.
• C) Thiopental 3 mg/kg IV — barbiturates are the preferred agents for emergency intubation in COPD because their profound GABA-A-mediated suppression of the cough reflex prevents the reflex bronchospasm that occurs during laryngoscopy and intubation, and their cardiovascular depression is mild at reduced doses in euvolemic patients.
• D) Dexmedetomidine infusion at 1 mcg/kg over 10 minutes — its alpha-2 mechanism reduces sympathetic tone to airway smooth muscle, producing bronchodilation through reduction of adrenergic bronchoconstriction, and its preservation of spontaneous ventilation allows a semi-awake intubation technique that avoids the risks of full induction in a hemodynamically unstable patient.
• E) Etomidate 0.3 mg/kg IV — its hemodynamic neutrality addresses the hypotension, and its complete lack of effect on airway smooth muscle tone makes it bronchospasm-neutral; because it neither bronchodilates nor bronchoconstricts, it provides a pharmacologically clean induction that avoids the cardiovascular stimulation of ketamine, which could worsen the patient's work of breathing by increasing cardiac oxygen demand.

10. A 74-year-old man is started on a dexmedetomidine infusion at 0.6 mcg/kg/hr for ICU sedation following elective aortic valve replacement. He is not on any rate-slowing medications. Twenty minutes into the infusion, the cardiac monitor alarms: the rhythm shows sinus pauses of 3.2 seconds with junctional escape beats at 38 bpm. A review of his pre-operative ECG (obtained 2 days before surgery) shows Mobitz type I (Wenckebach) second-degree atrioventricular block with occasional dropped beats. Which patient characteristic most directly predicted this risk and why?

• A) His age of 74 years — advanced age alone is the primary risk factor for dexmedetomidine-induced sinus pauses because age-related fibrosis of the sinoatrial node reduces its intrinsic pacemaker rate, creating a situation where any reduction in sympathetic tone from any cause will produce clinically significant bradycardia or sinus pauses.
• B) His recent cardiac surgery — cardiopulmonary bypass produces transient sinoatrial node ischemia in all patients that resolves within 48 hours; dexmedetomidine administered within this 48-hour post-bypass window consistently produces sinus pauses because the injured sinoatrial node is unable to respond to sympathetic withdrawal with adequate escape pacemaker activity.
• C) His pre-existing Mobitz type I (Wenckebach) second-degree atrioventricular block — this conduction abnormality indicates impaired AV nodal conduction at baseline; dexmedetomidine's central sympatholytic effect reduces heart rate and augments vagal tone at the AV node; in a patient with already-marginal AV nodal conduction, this additional vagally-mediated slowing can produce complete AV nodal conduction failure, sinus pauses, and reliance on junctional or ventricular escape rhythms; pre-existing conduction abnormalities are a well-recognized risk factor for severe dexmedetomidine-associated bradycardia.
• D) His post-operative hyperkalemia — aortic valve replacement consistently produces transient hyperkalemia from cardioplegic solution containing potassium, and hyperkalemia reduces the resting membrane potential of sinoatrial node cells below the threshold for spontaneous depolarization; dexmedetomidine's sympatholytic effect has no independent role in the bradycardia, which is entirely attributable to the post-operative electrolyte abnormality.
• E) His lack of beta-blocker therapy — patients who are not taking beta-blockers have higher baseline sympathetic tone; when dexmedetomidine reduces this sympathetic tone, the relative withdrawal from a high-sympathetic-tone baseline produces a paradoxically greater bradycardic response than in patients who are already beta-blocked and therefore accustomed to lower sympathetic stimulation of the sinoatrial node.

11. A 48-year-old woman undergoes a 3-hour laparoscopic colectomy under TIVA with propofol and remifentanil at 0.2 mcg/kg/min. At the time of skin closure, the anesthesiologist administers morphine 8 mg IV. Remifentanil is stopped at the completion of skin closure, and propofol is stopped 6 minutes later. The patient emerges alert and oriented but reports severe pain at an intensity of 9 out of 10 within 3 minutes of waking, before the team has had time to administer any additional analgesic. The anesthesiologist appears surprised. Which pharmacological explanation best accounts for the patient's pain?

• A) The morphine 8 mg IV was metabolized faster than expected because remifentanil co-administration induced hepatic CYP3A4 activity — the elevated CYP3A4 during the remifentanil infusion accelerated morphine glucuronidation, reducing effective morphine plasma concentrations to sub-analgesic levels by the time of emergence; the solution is to use a non-CYP3A4-dependent opioid such as hydromorphone for transition analgesia in future TIVA cases.
• B) The pain reflects opioid-induced hyperalgesia from remifentanil alone — 3 hours of remifentanil at 0.2 mcg/kg/min is sufficient to produce complete sensitization of all spinal nociceptive pathways, such that morphine at any dose administered before emergence would be unable to provide analgesia against the hyperalgesic baseline; the only effective management is ketamine given before stopping remifentanil.
• C) The morphine dose was inadequate for this patient's body weight — 8 mg IV is below the analgesic threshold in patients over 70 kg, and the pharmacodynamic relationship between morphine dose and analgesia requires weight-based dosing of at least 0.15 mg/kg IV to achieve meaningful mu-opioid receptor occupancy at spinal and supraspinal sites.
• D) The timing was insufficient — morphine administered IV at wound closure does not produce reliable analgesia for 15 to 30 minutes after administration because its onset is determined by the rate of transfer from plasma to the CNS effect site; remifentanil, with its context-insensitive half-time of 3 to 5 minutes, was eliminated from the effect site within minutes of stopping the infusion; the patient emerged fully conscious with complete loss of remifentanil analgesia before morphine had achieved adequate effect-site concentrations — the analgesic gap was not prevented but merely delayed by a few minutes by the late morphine administration.
• E) The pain is caused by the pneumoperitoneum (CO2 gas insufflated into the abdominal cavity for laparoscopic surgery) not yet having been fully evacuated at the time of emergence — residual CO2 irritates the diaphragm and peritoneum through carbonic acid formation, producing referred shoulder tip pain that is resistant to opioid analgesia and requires ketorolac or a diaphragmatic nerve block rather than additional opioids.